Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

87.00GBp
11:35am EDT
Change (% chg)

-11.05 (-11.27%)
Prev Close
98.05
Open
98.25
Day's High
99.75
Day's Low
86.10
Volume
14,642,297
Avg. Vol
6,149,814
52-wk High
151.50
52-wk Low
68.00

Select another date:

Fri, Apr 20 2018

BRIEF-Vectura Says CFO Decided To Leave Group

* CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR ANDREW DERODRA HAS DECIDED TO LEAVE GROUP

CORRECTED-UPDATE 1-UK's Vectura posts wider 2017 loss, revenue rise

March 21 British drugmaker Vectura reported a worse-than-expected pretax loss for the full year on Wednesday, dragged by lower royalties and higher costs related to the SkyePharma deal.

BRIEF-Vectura Group Posts FY Reported Revenue Of 148.0 Mln Pounds‍​

* FULL YEAR REPORTED REVENUE OF £148.0 MILLION, IN LINE WITH BOARD EXPECTATIONS (REPORTED 9M 2016: £126.5 MILLION)‍​

BRIEF-Vectura Group Anticipates FY 2017 Revenue In Line With Board's Expectations

* FULL YEAR 2017 REVENUE ANTICIPATED TO BE IN LINE WITH BOARD'S EXPECTATIONS

BRIEF-Vectura group announces buyback to return up to £15 million of capital to shareholders​

* ‍vectura group plc (lse: vec) ("vectura", " group"), announces that board has approved a share buyback to return up to £15 million of capital to shareholders​ Source text for Eikon: Further company coverage: (Reporting by Lawrence White)

BRIEF-Vectura confident on outlook for Novartis inhaler products

* Q3 2017 net sales of $101 million for ultibro ® breezhaler ® and $37 million for seebri ® breezhaler​

Select another date: